AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34725926 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-designed service pathway including peer support and family member intervention as core service components.
Number of subjects: 0
Study 34725926 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth defined the primary outcome measure and contributed to secondary measures.
Number of subjects: 0
Study 34725926 — intervention group
Group type: EXPERIMENTAL
Intervention: Training research staff on working with youth and family members.
Number of subjects: 0
Study 34725926 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth and family members as co-presenters and manuscript co-authors in knowledge translation activities.
Number of subjects: 0
Study 34631520 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 25
Study 34631520 — intervention group
Group type: COMPARATOR
Intervention: Local Anesthesia (LA)
Number of subjects: 25
Study 35313967 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (PBMNCs)
Number of subjects: 50
Study 35313967 — intervention group
Group type: COMPARATOR
Intervention: Purified CD34+ cells (PCCs)
Number of subjects: 50
Study 34785589 — intervention group
Group type: EXPERIMENTAL
Intervention: AI‐QCT analysis of plaque volume (PV) and calcified plaque (CP) in patients >65 years
Number of subjects: 303
Study 34785589 — intervention group
Group type: EXPERIMENTAL
Intervention: AI‐QCT analysis of % percent atheroma volume (%PAV) of low-density non-calcified plaque (LD‐NCP) in patients <65 years
Number of subjects: 303
Study 34785589 — intervention group
Group type: EXPERIMENTAL
Intervention: AI‐QCT analysis of plaque characteristics in obstructive vs non-obstructive lesions in younger patients
Number of subjects: 303
Study 34785589 — intervention group
Group type: EXPERIMENTAL
Intervention: AI‐QCT analysis of lesion types in older patients
Number of subjects: 303
Study 33461782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 600 mg
Number of subjects: 1538
Study 33461782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1538
Study 33461782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 1538
Study 32942627 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Nutrition Advice (PNA)
Number of subjects: 155
Study 32942627 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Nutrition Advice (PNA) with goal-setting
Number of subjects: 155
Study 32942627 — intervention group
Group type: COMPARATOR
Intervention: Generic Nutrition Advice (GNA)
Number of subjects: 155
Study 32942627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no advice)
Number of subjects: 155
Study 32576079 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical experiential training
Number of subjects: 0
Study 32576079 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional lecture teaching
Number of subjects: 0
Study 32576079 — intervention group
Group type: COMPARATOR
Intervention: Control group (without safety/health education and training)
Number of subjects: 0
Study 33546949 — intervention group
Group type: EXPERIMENTAL
Intervention: 2008–2012 salt intake
Number of subjects: 3844
Study 33546949 — intervention group
Group type: EXPERIMENTAL
Intervention: 2018–2019 salt intake
Number of subjects: 3844
Study 33546949 — intervention group
Group type: COMPARATOR
Intervention: Salt intake reduction
Number of subjects: 3844
Study 32290072 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Plus intervention
Number of subjects: 260
Study 36239290 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 42
Study 36239290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 32215700 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 1505
Study 32215700 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (adjusted for baseline variables)
Number of subjects: 1505
Study 32215700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1505
Study 35796651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin plus saline
Number of subjects: 12
Study 35796651 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment plus GIP(3‐30)NH2
Number of subjects: 12
Study 33772963 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of antihaemophilic factor (recombinant)
Number of subjects: 60
Study 33772963 — intervention group
Group type: COMPARATOR
Intervention: Bolus infusion (BI) of antihaemophilic factor (recombinant)
Number of subjects: 60
Study 32762701 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 96
Study 32762701 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 96
Study 36180143 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-part breathing exercise plus counseling for smoking cessation once a week for 12 weeks
Number of subjects: 43
Study 36180143 — intervention group
Group type: COMPARATOR
Intervention: Counseling for smoking cessation once a week for 12 weeks
Number of subjects: 43
Study 36180143 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-part breathing exercise plus counseling for smoking cessation
Number of subjects: 43
Study 36180143 — intervention group
Group type: COMPARATOR
Intervention: Counseling for smoking cessation
Number of subjects: 43
Study 33844358 — intervention group
Group type: EXPERIMENTAL
Intervention: 3v3 small-sided games
Number of subjects: 0
Study 33844358 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis (PCA) scores
Number of subjects: 0
Study 33629758 — intervention group
Group type: EXPERIMENTAL
Intervention: Immigrant‐origin youth
Number of subjects: 179
Study 33629758 — intervention group
Group type: COMPARATOR
Intervention: Non‐immigrant‐origin youth
Number of subjects: 179
Study 33629758 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bystander responses
Number of subjects: 179
Study 33629758 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander responses to bullying and retaliation
Number of subjects: 179
Study 36360995 — intervention group
Group type: EXPERIMENTAL
Intervention: Online supervised exercise program (from 8‐10 to 38‐39 weeks of pregnancy)
Number of subjects: 260
Study 33459481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward round checklist
Number of subjects: 124
Study 32800532 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone 30 mg IV infused over 60 min
Number of subjects: 34
Study 35768101 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body photobiomodulation therapy (NovoTHOR)
Number of subjects: 20
Study 34812070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multiplanar trunk training coupled with dual-task exercises
Number of subjects: 74
Study 32343890 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 245
Study 32343890 — intervention group
Group type: COMPARATOR
Intervention: Control (enzalutamide or abiraterone)
Number of subjects: 245
Study 35088753 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 107
Study 35088753 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (40 mg/d for 12 weeks)
Number of subjects: 107
Study 34111071 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive stimulation and nutrition interventions
Number of subjects: 1058
Study 34111071 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-item motor composite of the Brief Form of Bruininks Oseretsky Test
Number of subjects: 1058
Study 32588194 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating (ALT) BFR exercise
Number of subjects: 20
Study 32588194 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral (UNI) BFR exercise
Number of subjects: 20
Study 36331522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 36331522 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg empagliflozin
Number of subjects: 24
Study 36331522 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg empagliflozin
Number of subjects: 24
Study 33086400 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab 1.5 mg/kg once-weekly subcutaneous
Number of subjects: 112
Study 32389606 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-concordant care
Number of subjects: 405
Study 32389606 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-discordant care
Number of subjects: 405
Study 32389606 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertain focus of care
Number of subjects: 405
Study 32389606 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-concordant care for patients prioritizing extending life
Number of subjects: 405
Study 32389606 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-discordant care for patients prioritizing extending life
Number of subjects: 405
Study 32389606 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertain focus of care for patients prioritizing extending life
Number of subjects: 405
Study 32389606 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-concordant care for patients prioritizing relief of pain and discomfort
Number of subjects: 405
Study 32389606 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-discordant care for patients prioritizing relief of pain and discomfort
Number of subjects: 405
Study 32389606 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertain focus of care for patients prioritizing relief of pain and discomfort
Number of subjects: 405
Study 32389606 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk of goal-discordant care for patients prioritizing relief of pain and discomfort vs extending life
Number of subjects: 405
Study 35446293 — intervention group
Group type: EXPERIMENTAL
Intervention: TPDLP (transperineal pelvic drainage combined with lateral position)
Number of subjects: 60
Study 35446293 — intervention group
Group type: COMPARATOR
Intervention: N-TPDLP (standard arm)
Number of subjects: 60
Study 35446293 — intervention group
Group type: EXPERIMENTAL
Intervention: TPDLP
Number of subjects: 60
Study 35446293 — intervention group
Group type: COMPARATOR
Intervention: N-TPDLP
Number of subjects: 60
Study 33541372 — intervention group
Group type: EXPERIMENTAL
Intervention: Nourish
Number of subjects: 903
Study 33541372 — intervention group
Group type: COMPARATOR
Intervention: Control (Delayed)
Number of subjects: 903
Study 32758038 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (0.1 mmol·kg‐1·day‐1)
Number of subjects: 30
Study 35742698 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5% nicotine EC
Number of subjects: 84
Study 35742698 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0% nicotine) EC
Number of subjects: 84
Study 33025405 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap group (AACGN + ICMGN)
Number of subjects: 29
Study 33025405 — intervention group
Group type: COMPARATOR
Intervention: AACGN-only group
Number of subjects: 29
Study 32672670 — intervention group
Group type: EXPERIMENTAL
Intervention: MINIject (iSTAR Medical, Wavre, Belgium)
Number of subjects: 26
Study 35747192 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ-MBZ (Temozolomide + Mebendazole)
Number of subjects: 88
Study 35747192 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU-MBZ (Lomustine + Mebendazole)
Number of subjects: 88
Study 33733311 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized-Targeted Cognitive Training
Number of subjects: 88
Study 33733311 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 88
Study 32624473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Cardiac Rehabilitation Program (TCCRP) supervised three times a week for 3 months
Number of subjects: 150
Study 32624473 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise rehabilitation supervised three times a week for 3 months
Number of subjects: 150
Study 32624473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Cardiac Rehabilitation Program (TCCRP)
Number of subjects: 150
Study 32624473 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise rehabilitation
Number of subjects: 150
Study 35543853 — intervention group
Group type: EXPERIMENTAL
Intervention: IVB + normal vitamin D levels (Group 1)
Number of subjects: 83
Study 35543853 — intervention group
Group type: COMPARATOR
Intervention: IVB + vitamin D insufficient/deficient (Group 2)
Number of subjects: 83
Study 35543853 — intervention group
Group type: EXPERIMENTAL
Intervention: IVB + vitamin D insufficient/deficient + oral vitamin D supplementation (Group 3)
Number of subjects: 83
Study 33227785 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Control Treatment (PCT)
Number of subjects: 221
Study 33227785 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Therapy (PFPP)
Number of subjects: 221
Study 33227785 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice and Random Conditions
Number of subjects: 221
Study 33227785 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Waiting List)
Number of subjects: 221
Study 34922058 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftaroline fosamil
Number of subjects: 1976
Study 34922058 — intervention group
Group type: COMPARATOR
Intervention: comparator
Number of subjects: 1976
Study 35221706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide plus mebeverine
Number of subjects: 150
Study 35221706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline plus mebeverine
Number of subjects: 150
Study 35221706 — intervention group
Group type: COMPARATOR
Intervention: Mebeverine
Number of subjects: 150
Study 32618034 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) education program during two face‐to‐face sessions, along with routine health education (two 1‐h lectures) over a 2‐wk period
Number of subjects: 112
Study 32618034 — intervention group
Group type: COMPARATOR
Intervention: Routine health education (two 1‐h lectures)
Number of subjects: 112
Study 35631279 — intervention group
Group type: EXPERIMENTAL
Intervention: EGG (two eggs per day)
Number of subjects: 30
Study 35631279 — intervention group
Group type: COMPARATOR
Intervention: SUB (egg substitute)
Number of subjects: 30
Study 33259720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 60
Study 35683985 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-and-treat approach for intestinal parasites at the individual level
Number of subjects: 121
Study 35683985 — intervention group
Group type: COMPARATOR
Intervention: Annual albendazole at the individual level
Number of subjects: 121
Study 35683985 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms (including test-and-treat and albendazole)
Number of subjects: 121
Study 32393194 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with a longstanding mental health condition
Number of subjects: 4787
Study 32393194 — intervention group
Group type: COMPARATOR
Intervention: Women without a longstanding mental health condition
Number of subjects: 4787
Study 32515891 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training Group (ETG)
Number of subjects: 77
Study 32515891 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training Group (STG)
Number of subjects: 77
Study 33021938 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for interpreting deep image classifiers using discrete masks and generative adversarial networks.
Number of subjects: 0
Study 33021938 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for interpreting deep image classifiers.
Number of subjects: 0
Study 35022958 — intervention group
Group type: EXPERIMENTAL
Intervention: ACO
Number of subjects: 23643
Study 35022958 — intervention group
Group type: COMPARATOR
Intervention: Non-ACO
Number of subjects: 23643
Study 32985240 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary protraction therapy in UCLP group
Number of subjects: 52
Study 32985240 — intervention group
Group type: COMPARATOR
Intervention: Maxillary protraction therapy in noncleft group
Number of subjects: 52
Study 32985240 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary protraction therapy in both groups
Number of subjects: 52
Study 32375104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulacimstat 25 mg twice daily for 6 months
Number of subjects: 107
Study 32375104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 95148513 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35531757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (20 mL of 2% solution)
Number of subjects: 99
Study 35531757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg/kg)
Number of subjects: 99
Study 35531757 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 99
Study 34749782 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST), administered 2-3 days per week over seven weeks, maximum of 21 treatments.
Number of subjects: 260
Study 34749782 — intervention group
Group type: COMPARATOR
Intervention: Right unilateral ultra-brief pulse width electroconvulsive therapy (RUL-UB-ECT), administered 2-3 days per week over seven weeks, maximum of 21 treatments.
Number of subjects: 260
Study 34749782 — intervention group
Group type: EXPERIMENTAL
Intervention: MST or RUL-UB ECT (both groups),
Number of subjects: 260
Study 34656515 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy at 4 points with a diode laser at 810 nm wavelength, 6 J (100 mW, 60 seconds/point)
Number of subjects: 13
Study 34656515 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) therapy
Number of subjects: 13
Study 34656515 — intervention group
Group type: COMPARATOR
Intervention: SHAM (laser irradiation simulation)
Number of subjects: 13
Study 35261590 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.375% bupivacaine
Number of subjects: 60
Study 35261590 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mL of 0.375% bupivacaine
Number of subjects: 60
Study 35261590 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of 0.375% bupivacaine
Number of subjects: 60
Study 32674604 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic, resistance, and combined training
Number of subjects: 104
Study 33377343 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser treatment
Number of subjects: 113
Study 33377343 — intervention group
Group type: COMPARATOR
Intervention: Control group (post-cheiloplasty)
Number of subjects: 113
Study 35969212 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic resin anterior bite plane (ABP)
Number of subjects: 34
Study 35969212 — intervention group
Group type: COMPARATOR
Intervention: Thermoplastic materials anterior bite plane (TBP)
Number of subjects: 34
Study 35969212 — intervention group
Group type: COMPARATOR
Intervention: Comparison between ABP and TBP
Number of subjects: 34
Study 34256171 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic therapy with MPQ, intracanal medication, and 2 applications of aPDT (0.005% methylene blue, 660 nm, 90 seconds)
Number of subjects: 50
Study 34256171 — intervention group
Group type: COMPARATOR
Intervention: Endodontic Therapy with Mechanical Chemical Preparation (MPQ) and intracanal medication
Number of subjects: 50
Study 34256171 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT
Number of subjects: 50
Study 32516821 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider interaction in rehabilitation setting
Number of subjects: 618
Study 32516821 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider interaction in medical setting
Number of subjects: 618
Study 32516821 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider interaction in consumer electronics setting
Number of subjects: 618
Study 32516821 — intervention group
Group type: COMPARATOR
Intervention: Preappointment responses (control condition)
Number of subjects: 618
Study 35060200 — intervention group
Group type: EXPERIMENTAL
Intervention: S1
Number of subjects: 64
Study 35060200 — intervention group
Group type: COMPARATOR
Intervention: S2
Number of subjects: 64
Study 32340800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 57
Study 32340800 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 57
Study 36459119 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy
Number of subjects: 253
Study 36459119 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 253
Study 36459119 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with disease worsening
Number of subjects: 253
Study 36459119 — intervention group
Group type: COMPARATOR
Intervention: Patients without disease worsening
Number of subjects: 253
Study 33197677 — intervention group
Group type: EXPERIMENTAL
Intervention: d3RP-NF2 program
Number of subjects: 45
Study 33197677 — intervention group
Group type: COMPARATOR
Intervention: Health-Enhancement program (Control)
Number of subjects: 45
Study 34302588 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to the recitation of the Surah Al‐Inshirah during labor
Number of subjects: 126
Study 34543779 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of antiseizure medication (ASM)
Number of subjects: 60
Study 34543779 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of antiseizure medication (ASM)
Number of subjects: 60
Study 34543779 — intervention group
Group type: COMPARATOR
Intervention: 4 weeks of ASM
Number of subjects: 60
Study 34543779 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of ASM
Number of subjects: 60
Study 34543779 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with disabilities at randomization
Number of subjects: 60
Study 34894161 — intervention group
Group type: EXPERIMENTAL
Intervention: Majority-message condition
Number of subjects: 158
Study 34894161 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority-message condition
Number of subjects: 158
Study 34894161 — intervention group
Group type: COMPARATOR
Intervention: No-message condition
Number of subjects: 158
Study 34894161 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Dominance Orientation (SDO)
Number of subjects: 158
Study 34894161 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusive Work Environment (IWC)
Number of subjects: 158
Study 32064691 — intervention group
Group type: EXPERIMENTAL
Intervention: Active kava-drinking participants
Number of subjects: 40